Fig. 4From: Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapyClinical response to CKI therapy (R1) and subsequent response to CKI + TT treatment (R2)Back to article page